Addex Therapeutics Posts Wider H1 Attributable Net Loss; Operating Loss Narrows

02:01 AM EDT, 09/28/2026 (MT Newswires) -- Addex Therapeutics (ADXN.SW) on Monday reported a wider net loss for the first half of 2026, while operating loss narrowed year over year. Net loss attributable to equity holders of the company for the six months ended June 30 was 3.5 million francs, compared with a loss of 3.3 million francs earlier. Loss per share remained stable at 0.03 franc. The pharmaceutical company's operating loss was 1.1 million francs, compared with 1.3 million francs a year ago.